Soonmyung Paik
Yonsei University
255 Papers
2.7K Citations
Soonmyung Paik is an academic researcher from Yonsei University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 69, co-authored 240 publications. Previous affiliations of Soonmyung Paik include Temple University & Georgetown University.
Chat about Author
Papers
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Hyung Soon Park,Joohyuk Sohn,Seung Il Kim,Seho Park,Hyung Seok Park,Seul Ghi Gho,Hyun Cheol Chung,Soonmyung Paik,Gun Min Kim +8 more
TL;DR: Among patients with HER2+ MBC, HR status is a possible predictive biomarker of a durable response to trastuzumab-based therapy.
4
Regulation of proliferation and differentiation of normal and malignant breast: new factors and neu paradoxes
Robert B. Dickson,Soonmyung Paik +1 more
TL;DR: It is hoped that isolation of candidate ligands for the receptor will provide new tools for study of the biological role of c-erb B-2, which has mixed effects on growth and stimulation of cellular differentiation.
3
Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution.
TL;DR: OncotypeDx suggests that any gene expression–based prognostic tests can identify patients who do not need chemotherapy among those with ER+/N− BC, and meta-analysis of BC microarray gene expression profiling data suggests this.
3
Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial
Douglas T. Ross,Chungyeul Kim,Gong Tang,O. M. Mejia,Rodney A. Beck,Brian Z. Ring,Robert S. Seitz,Soonmyung Paik,J. P. Constantino,Norman Wolmark +9 more
TL;DR: This study examined interaction between the test and chemotherapy in the B20 trial and identified high and low risk groups that both showed significant improvement upon treatment with cytotox...
3
Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
María Agustina Chavez,Jieling Miao,Lajos Pusztai,Matthew P. Goetz,Priya Rastogi,Patricia A. Ganz,Eleftherios (Terry) Mamounas,Soonmyung Paik,Hanna Bandos,Wajeeha Razaq,Anne O'Dea,Virginia G. Kaklamani,Andrea Silber,Lisa Flaum,Eleni Andreopolu,Joseph Baar,Albert Wendt,Jennifer Fu Carney,Priyanka Sharma,Julie R. Gralow,Danika L. Lew,William E. Barlow,Gabriel N. Hortobagyi +22 more
TL;DR: In this article , the role of everolimus in combination with ET in the adjuvant setting among patients with high-risk hormone receptor-positive, HER2-negative BC was evaluated.
3